Lower Vs. Standard Insulin-Dextrose Doses for Treating Mild to Moderate Hyperkalemia in the Emergency Department

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
Hyperkalemia
Interventions
PROCEDURE

Lower Dose Therapy

The group receiving the lower-dose therapy consists of 5 units of Actrapid (insulin) with 25cc of Dextrose 50%. This intervention is the focus of the clinical trial and is being investigated to determine if it achieves a comparable reduction in potassium levels with fewer potential complications. The aim is to establish it as a non-inferior alternative to conventional-dose therapy in the management of mild and moderate hyperkalemia.

PROCEDURE

Conventional Dose Therapy

The group receiving the conventional-dose therapy, consisting of 10 units of Actrapid (insulin) with 50cc of Dextrose 50%, which is currently in use as a standard practice in emergency departments for managing mild and moderate hyperkalemia. This dosing regimen aligns with established clinical guidelines and is widely accepted as an effective approach in controlling potassium levels.

Trial Locations (1)

Unknown

University Malaya Medical Centre, Kuala Lumpur

All Listed Sponsors
lead

University of Malaya

OTHER

NCT06724991 - Lower Vs. Standard Insulin-Dextrose Doses for Treating Mild to Moderate Hyperkalemia in the Emergency Department | Biotech Hunter | Biotech Hunter